Before you leave...
Take 20% off your first order
20% off
Enter the code below at checkout to get 20% off your first order
Discover summer reading lists for all ages & interests!
Find Your Next Read
Revised and updated: the fascinating story of the creation of GLP-1s and their revolutionary impact on public health.
A "cure" for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates a hormone in the stomach called GLP-1, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries--from healthcare to fast food to fashion--and it has quickly made its creator, Denmark's Novo Nordisk, the most valuable company in Europe. But the impact of GLP-1s goes far beyond billion-dollar profits; a true long-term cure for obesity could save 40 percent of American adults from dangerous, preventable illnesses. And as more potential benefits emerge, one question looms in the minds of investors, healthcare workers, and politicians: Are these drugs too good to be true?
Thanks for subscribing!
This email has been registered!
Take 20% off your first order
Enter the code below at checkout to get 20% off your first order